We’re excited to announce that OnCusp Therapeutics has received FDA Fast Track Designation for our lead program, CUSP06, a promising treatment for platinum-resistant ovarian cancer. This designation accelerates the development of CUSP06 and brings us one step closer to providing new hope for patients in need of effective therapies. The early results from our Phase 1 trial have been encouraging, and we are committed to working closely with the FDA to bring this innovative treatment to market. Learn more about our progress here: https://lnkd.in/ezmrY6ZV. #OnCuspTherapeutics #FDA #FastTrack #CUSP06 #OvarianCancer #Biopharma #CancerResearch
关于我们
OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.
- 网站
-
https://www.oncusptx.com
OnCusp Therapeutics的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- New York，New York
- 类型
- 私人持股
- 创立
- 2021
- 领域
- Biotech、Pharmaceutical和Oncology
地点
OnCusp Therapeutics员工
动态
-
?We are thrilled to be named a member of BioSpace NextGen Class of 2025, the top life science startups to watch this year.
BioSpace is proud to present its NextGen Class of 2025. Our list showcases 25 of the industry’s most promising up-and-coming companies. This is the 11th year BioSpace has highlighted the most anticipated new biopharma companies from across the U.S.?Who made the list? https://lnkd.in/gcvnWyE8
-